Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.37 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.36 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NEK2 | P51955 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29345998 | 0.98 | CRBN (0.36) | CRBNOTUD7BFKBP5GRIN1GRIN2A | |
| SCHEMBL21224581 | 0.98 | CRBN (0.38) | CRBNOTUD7BFKBP5GRIN1GRIN2A | |
| SCHEMBL23009670 | 0.96 | CRBN (0.35) | CRBNOTUD7BFKBP5GRIN1GRIN2A | |
| SCHEMBL23009445 | 0.94 | CRBN (0.36) | CRBNOTUD7BFKBP5GRIN1GRIN2A | |
| SCHEMBL2023430 | 0.91 | CRBN (0.39) | CRBNOTUD7BFKBP5GRIN1GRIN2A | |
| SCHEMBL6673999 | 0.91 | FKBP5 (0.39) | CRBNOTUD7BFKBP5GRIN1GRIN2A | |
| SCHEMBL23009666 | 0.89 | CRBN (0.38) | CRBNOTUD7BFKBP5GRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL2637274 | 0.89 | CRBN (0.38) | CRBNOTUD7BFKBP5GRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL2026185 | 0.89 | CRBN (0.38) | CRBNOTUD7BFKBP5GRIN1GRIN2A | |
| SCHEMBL9129408 | 0.89 | CRBN (0.40) | CRBNOTUD7BFKBP5GRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578072-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20210040095-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578072-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN2B | CRBN 3025/4885OTUD7B 3145/4885FKBP5 340/4885 |
| US-20210040095-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2B | CRBN 3025/4885OTUD7B 3145/4885FKBP5 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.